Qingxin Mu

Accepting Students to Lab: Yes

Education

BE, Pharmaceutical Preparation, Henan University, China, 2005

PhD, Medicinal Chemistry, Shandong University, China, 2010

Research Interests

• Development of advanced combination therapeutic delivery approaches
• Translational investigations of drug combination nanoparticles for metastatic cancer treatment
• Nanoformulation-biological system interactions

Courses Taught

• PCEUT505
• PCEUT 531
• PCEUT 580
• PCEUT 583

Biography

Dr. Mu embarked on his academic journey in the United States in 2007 as a Ph.D. exchange student in the Department of Chemical Biology and Therapeutics at St. Jude Children’s Research Hospital, where he held the position of International Research Scholar (2007-2009). After PhD graduation, he continued as a postdoc research associate in the same department (2010-2012). From 2012-2017, he furthered his postdoctoral research in the Department of Pharmaceutical Chemistry at the University of Kansas and then in the Department of Materials Science and Engineering at the University of Washington (UW). From 2017-2021, he served as a Research Scientist in UW School of Pharmacy (UWSOP) Department of Pharmaceutics, before transferring into a faculty position in September 2021.

Over the past 15+ years, in addition to pharmaceutical sciences, Dr. Mu received multidisciplinary research training in the fields of chemistry, materials science, nanotechnology, cell and molecular biology, and immunology. As of 2023, Dr. Mu’s research work has resulted in nearly 60 publications (journal articles, patents, editorials, and book chapters), with over 4000 citations. He has served on the editorial boards of 6 international peer-reviewed journals such as the Journal of Pharmaceutical Sciences, Frontiers in Bioengineering and Biotechnology, and Frontiers in Oncology. He has also participated in the reviewer panels of two NIH study sections. Dr. Mu’s long-term research goal is to develop advanced and well-characterized combination therapeutic delivery nanosystems for metastatic cancers and beyond. As the principal investigator, he has obtained and managed multiple intra- and extramural research grants including UW Royalty Research Fund, UWSOP Faculty Innovation Fund, UWSOP DMTSPR Consortium, and NIH/NCI R21.

Selected Publications:

https://www.ncbi.nlm.nih.gov/myncbi/16mTPZdlXqdMRo/bibliography/public/

1. Jia J,* Mu Q,* Zhou H.* Editorial: Biomedical applications and health impacts of emerging nanostructured materials. Frontiers in Bioengineering and Biotechnology, 2023, 11, 1282946.
2. Zhang M, Mu Q, Lin G, Iron oxide nanoparticle for targeted chemo-immunotherapy. US Patent App. 17/821,794.
3. Ho RJY. Griffin JI, Mu Q, Wu Y, Yu J. Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs. PCT Int. Appl. WO2021173870A1 20210902.
4. Zhu L, Mu, Q,* Yu J, Griffin JI, Xu X, Ho RJY.* ICAM-1 targeted drug combination nanoparticles enhanced gemcitabine-paclitaxel exposure and breast cancer suppression in mouse models. Pharmaceutics, 2022, 14, 89.
5. Bai X, Wang J, Mu Q,* Su G.* In vivo protein corona formation: characterizations, effects on engineered nanoparticles’ biobehaviors, and applications. Frontiers in Bioengineering and Biotechnology, 2021, 9:646708.
6. Mu Q, Lin G, Jeon M, Wang H, Yen T, Revia RA, Halbert M, Zhang M.* Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. Materials Today, 2021, 50, 149-169.
7. Yu J,+ Mu Q,+ Perazzolo S, Griffin JI, Zhu L, McConnachie LA, Shen DD, Ho RJY,* Novel long-acting nanoparticles composed of gemcitabine and paclitaxel enhance localization of both drugs in metastatic breast cancer nodules. Pharmaceutical Research. 37(10),197
8. Mu Q, Lin, G, Stephen ZR, Wang H, Chang F, Patton VK, Gebhart NR, Press OW, Zhang M.* In vivo serum enabled production of ultrafine nanotherapeutics for cancer treatment. Materials Today, 2020, 38, 10-23.
9. Gao Y,+ Mu Q,+ Zhu L, Li Z, Ho RJY.* Optimizing a novel Au-grafted lipid nanoparticle through chelation chemistry for high photothermal biologic activity, Journal of Pharmaceutical Sciences, 2020, 5(109), 1780-1788.
10. Mu Q,+ Yu J,+ Griffin JI, Wu Y, Zhu L, McConnachie LA, Ho, RJY.* Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. PLOS ONE, 2020, 15(3):e0228557.
11. Mu Q,+ Wang H,+* Gu X, Stephen ZR, Yen TY, Chang FC,  Dayringer CJ, Zhang M.* Biconcave Carbon Nanodisk for Enhanced Drug Accumulation and Chemo-photothermal Tumor Therapy. Advanced Healthcare Materials. 2019, 1801505.
12. Mu Q,* Yan B.* Editorial: Nanoparticles in Cancer Therapy: Novel Concepts, Mechanisms and Applications. Frontiers in Pharmacology, 2019, doi: 10.3389/fphar.2018.01552.
13. Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho JY.* Translation of Combination Nanodrugs into Nanomedicines: Lessons Learned and Future Outlook, Journal of Drug Targeting, 2018, 26(5-6), 435-447.
14. Mu Q, Wang H, Zhang M.* (2016) Nanoparticles for Imaging and Treatment of Metastatic Breast Cancer. Opinion Drug Delivery, 2017, 14(1), 123-136.
15. Mu Q, Lin G, Patton VK, Wang K, Press OW, Zhang M.* (2016) Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy. Mater. Chem. B, 4(1), 32-36.
16. Mu Q, Kievit FM, Kant RJ, Lin G, Jeon M, Zhang M.* (2015) Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. Nanoscale 7(43), 18010-18014.
17. Mu Q, Jeon M, Hsiao M.-H, Patton VK, Wang K, Press OW, Zhang M.* (2015) Stable and Efficient Paclitaxel Nanoparticles for Targeted Glioblastoma Therapy. Healthcare Mater. 4(8), 1236-1245.
18. Hsiao M.-H,+ Mu Q.+, Stephen ZR, Fang C, Zhang M.* (2015) Hexanoyl Chitosan PEG Copolymer Coated Iron Oxide Nanoparticles for Hydrophobic Drug Delivery. ACS Macro Lett. 4(4), 403-407.
19. Jiao, Q., Li, L.W., Mu, Q.* Zhang, Q.* (2014) Immunomodulation of Nanoparticles in Nanomedicine Applications. BioMed Research International, Volume 2014, Article ID 426028.
20. Mu, Q., Jiang, G.B., Chen, L.X., Zhou, H.Y., Fourches, D., Tropsha, A., Yan, B.* (2014) Chemical Basis of Interactions between Engineered Nanoparticles and Biological Systems. Rev. 114(15), 7740-7781.
21. Mu, Q., Zhang, Y., Liu, A., Liang, N., Liu, Y., Mu, Y., Su, G., Yan, B.* (2013) Safety of Nanomaterials in Nanomedicinal Applications, Chapter in “Cancer Nanotechnology: Principles and Applications in Radiation Oncology”. 5, 49-61. Taylor & Francis Group.
22. Mu, Q., Su, G., Li, L., Gilbertson, B.O., Yu, L.H., Zhang, Q., Sun, S.-P., Jiang, G., Yan, B.* (2012) Size-dependent Cellular Uptake of Graphene Oxide Nanosheets. ACS Appl. Mater. Inter. 4(4), 2259-2266.
23. Mu, Q., Yang, L., Davis, J.C., Vankayala, R., Hwang, K.C., Zhao, J.C., Yan B.* (2010) Biocompatibility of Polymer Grafted Core/Shell Iron/Carbon Nanoparticles. Biomaterials, 31(19), 5083-5090.
24. Mu, Q., Zhai, S.M., Yan, B. * (2010) Real-time Monitoring of Cellular Responses to Carbon Nanotubes. Chapter in Methods Mol. Biol. 625, 85-94 — “Carbon Nanotubes: methods and protocols”, Humana Press.
25. Mu, Q., Broughton, D., Yan B. * (2009) Endosomal Leakage and Nuclear Translocation of Multi-Walled Carbon Nanotubes: Developing a Model for Cell Uptake. Nano Lett. 9(12), 4370-4375.
26. Mu, Q., Du G.Q., Chen T.S., Zhang B, Yan B.* (2009) Suppression of Human Bone Morphogenetic Protein Signaling by Carboxylated Single-Walled Carbon Nanotubes. ACS Nano, 3(5), 1139-1144.
27. Mu, Q., Li Z.W., Li X, Mishra S.R., Zhang B, Si Z.K., Yang L, Jiang W, Yan B.* (2009) Characterization of Protein Clusters of Diverse Magnetic Nanoparticles and Their Dynamic Interactions with Human Cells. Phys. Chem. C 113(14), 5390-5395.
28. Mu, Q., Liu, W., Xing, Y.H., Zhou, H.Y., Li, Z.W., Zhang, Y., Ji, L.H., Wang, F., Si, Z.K., Zhang, B., Yan, B.* (2008) Protein Binding by Functionalized Multiwalled Carbon Nanotubes Is Governed by the Surface Chemistry of Both Parties and the Nanotube Diameter. Phys. Chem. C 112(9), 3300-3307.